Clinical trials are moving from disconnected software tools toward integrated clinical development platforms that connect study design, electronic data capture, trial management, patient engagement, eConsent, eCOA, randomization, trial supply, safety and regulatory workflows.
Know The Companies, Investments, Products And Customer Needs Shaping Your Industry. Download Sample: https://www.towardshealthcare.com/download-sample/5029
The competitive landscape is led by large enterprise platforms such as Medidata, Veeva and Oracle, while IQVIA, Florence Healthcare, Clario, Advarra, Castor, Medable and Signant Health compete strongly in specific parts of the clinical-trial technology ecosystem.
The Leading Clinical Trial Platforms to Watch in 2026
1. Medidata
Medidata, part of Dassault Systèmes, remains one of the strongest clinical trial technology brands globally.
Its platform spans EDC, CTMS, RTSM, eCOA, patient engagement, clinical data management, AI and analytics, giving sponsors an integrated technology environment across the clinical development lifecycle.
The scale of Medidata’s data ecosystem is significant:
- 38,000+ clinical trials
- 12 million patients
- 1 million+ registered users
- Approximately 2,300 customers
- More than 25 years of clinical technology experience
- AI capabilities used across 500+ clinical studies and growing in 2026
Medidata is particularly strong among large pharmaceutical companies and global CROs.
Its competitive advantage is the combination of clinical data scale, Rave EDC, patient-facing technologies, analytics and AI.
In 2026, Medidata also launched Medidata Plus, an AI-native foundation designed to scale clinical portfolios and connect study, patient and data experiences.
2. Veeva Vault Clinical
Veeva has become one of the most important enterprise software providers in life sciences, and its Vault Clinical portfolio is increasingly competing directly with traditional clinical development platforms.
Veeva’s Development Cloud brings together technologies covering:
- Vault EDC
- Vault CTMS
- Vault eTMF
- Vault RTSM
- Vault CDMS
- Clinical operations
- Regulatory
- Safety
- Quality
The company’s overall scale is significant.
Veeva generated $3.20 billion in fiscal 2026 revenue, up 16% year over year, with subscription revenue of $2.68 billion, up 17%.
Veeva’s strength is its position as a life-sciences-native cloud platform rather than a generic enterprise software provider.
In 2026, Veeva also expanded its AI strategy through Veeva AI and Veeva Falcon, with agentic capabilities being developed across clinical, regulatory, safety and quality workflows.
For sponsors already using Veeva for regulatory, quality or commercial operations, expanding into clinical creates a strong platform-consolidation proposition.
3. Oracle Health and Life Sciences Clinical One
Oracle remains one of the most established enterprise technology companies in clinical research.
Its Oracle Clinical One platform supports clinical trial data collection and management across areas such as:
- EDC
- Randomization
- Trial supply management
- Clinical data management
- Patient engagement
- eConsent
- Study design
- Safety integration
Oracle reports that its clinical systems have supported more than 250,000 clinical studies and that 28 of the world’s 30 largest pharmaceutical companies use Oracle clinical systems.
This gives Oracle a particularly strong position among large pharmaceutical companies and CROs.
The company is also pushing Clinical One toward greater interoperability and decentralized trial capabilities, including EHR connectivity and integration with other Oracle safety and clinical technologies.
4. IQVIA Technologies
IQVIA occupies a distinctive position because it combines clinical technology, healthcare data, analytics and CRO services.
Its Orchestrated Clinical Trials platform connects technologies designed for sponsors, sites and patients.
IQVIA reports:
- 300+ customers
- 1,700+ studies
- 13,000+ technology experts
- Clinical technology experience extending across the full development lifecycle
IQVIA is particularly powerful for sponsors that want technology combined with real-world data, clinical operations, analytics and outsourced research services.
Its financial infrastructure is also substantial. IQVIA says 90% of the top 20 pharmaceutical companies use its Clinical Trial Financial Suite, with approximately $15 billion in payments made to sites and participants and operations across 200+ geographies.
This combination of data, technology and services differentiates IQVIA from pure-play software vendors.
5. Florence Healthcare
Florence has become one of the most important platforms for the research-site side of clinical trials.
Its Trial Operations Platform connects sponsors, CROs and research sites through technologies such as:
- eBinders
- SiteLink
- eTMF
- eConsent
- Site feasibility
- Contracting
- Study start-up
- Site workflows
- AI-enabled operations
Florence reports a network of approximately 65,000 research sites, more than 600 life-science organizations, 30,000 active protocols and coverage across 90+ countries.
Its site-centric model is important because clinical-trial technology has historically been fragmented between sponsor systems and site systems.
Florence’s 2026 platform strategy is increasingly focused on AI agents and interoperable workflows.
The company has also reported site-level benefits such as 30% faster study start-up and 12% higher study capacity in specific customer examples.
6. Clario
Clario is a leading specialist in clinical endpoint technology rather than a conventional CTMS or EDC vendor.
Its platform covers:
- eCOA
- Cardiac safety
- Medical imaging
- Respiratory endpoints
- Precision motion
- Connected devices
- Decentralized trial technologies
- AI-enabled evidence generation
Clario reports experience across:
- 30,000+ clinical trials
- 100+ countries
- 100+ languages
- 700+ FDA and EMA new drug approvals
- More than 50 years of experience
- 5,000+ imaging studies
Its positioning is especially strong in trials where objective endpoint measurement, imaging, cardiac safety, respiratory data or patient-reported outcomes are critical.
Clario also reports support for 250+ GLP-1 trial opportunities, making it relevant to the rapidly expanding obesity and metabolic-drug development market.
7. Advarra
Advarra is particularly strong in the research-site and institutional clinical research market.
Its ecosystem includes:
- CTMS
- IRB management
- eConsent
- Clinical trial management
- Research compliance
- Payments
- Site operations
Advarra’s strength comes from combining technology with a large institutional research network.
Its OnCore CTMS is widely used by academic medical centers, research institutions and other organizations managing complex clinical research portfolios.
This makes Advarra particularly relevant for academic research, hospitals and site networks, rather than only large global pharma sponsors.
8. Castor
Castor is a strong cloud-based clinical research platform with particular relevance to academic research, investigator-led studies, decentralized studies and smaller biotechnology organizations.
Its platform supports:
- EDC
- eConsent
- ePRO
- Randomization
- Data capture
- Clinical study management
- Patient recruitment
Castor also expanded its AI strategy with Castor Catalyst, launched in 2025 as an AI-powered platform designed to automate clinical-study tasks.
Its competitive positioning is different from Medidata and Oracle.
Rather than primarily targeting the largest global pharmaceutical enterprises, Castor can be attractive to organizations looking for flexibility, faster implementation and a more accessible clinical-research technology stack.
9. Medable
Medable is particularly important in the decentralized clinical trial and patient-centric research segment.
Its platform focuses on technologies that enable clinical research to move beyond traditional hospital and research-site environments.
This includes:
- Remote patient participation
- eConsent
- eCOA
- Telehealth
- Digital biomarkers
- Patient engagement
- Remote data collection
- Decentralized trial workflows
Medable is therefore particularly relevant for sponsors designing hybrid and decentralized trials.
The broader virtual clinical-trial market is increasingly competitive, with Medable, Medidata, IQVIA, Signant Health and Clario among the companies strengthening their positions through digital patient engagement, remote data capture and decentralized capabilities.
10. Signant Health
Signant Health has built a strong position around patient-centric clinical trial technology.
Its capabilities include:
- eCOA
- eConsent
- Patient engagement
- Digital health technologies
- Decentralized trials
- Endpoint data collection
- Clinical trial technology services
Signant is especially relevant when sponsors need to collect reliable patient-generated data outside traditional clinical settings.
Its positioning is therefore complementary to broader platforms such as Medidata, Veeva and Oracle.
2026 Clinical Trial Platform Statistics
| Platform | 2026-relevant scale indicator | Core strength | Best-known buyer segment |
|---|---|---|---|
| Medidata | 38,000+ trials; 12M patients; 2,300 customers | EDC, CTMS, patient, data and AI | Global pharma and CROs |
| Veeva | $3.20B FY2026 revenue; 16% growth | Clinical, regulatory, quality cloud | Enterprise biopharma |
| Oracle Clinical One | 250,000+ clinical studies; 28/30 top pharma | EDC, RTSM, clinical data | Large pharma and CROs |
| IQVIA Technologies | 300+ customers; 1,700+ studies; 13,000+ technology experts | Clinical technology + data + services | Pharma, biotech and CROs |
| Florence | 65,000+ sites; 600+ organizations; 90+ countries | Site operations and study start-up | Sponsors, CROs and sites |
| Clario | 30,000+ trials; 700+ FDA/EMA approvals; 100+ countries | Endpoint technology | Pharma and biotech |
| Advarra | Institutional research network and OnCore ecosystem | CTMS, IRB and research management | Academic medical centers |
| Castor | Cloud clinical research platform | EDC, eConsent, ePRO, AI | Biotech and academic research |
| Medable | Decentralized clinical research focus | Patient-centric and remote trials | Pharma and biotech |
| Signant Health | Global patient-centric trial technology | eCOA and digital endpoints | Pharma and CROs |
The figures above are company-reported or market-research figures and should not be interpreted as directly comparable market-share measurements.
Who Are the Buyers of Clinical Trial Platforms?
The buyer landscape is broader than simply pharmaceutical IT departments.
Pharmaceutical companies
Large pharmaceutical companies are the biggest enterprise buyers.
They typically require platforms capable of supporting hundreds of studies across multiple therapeutic areas and geographies.
Typical buyers include:
- Chief Clinical Officers
- Clinical Operations
- Data Management
- Biostatistics
- Medical Affairs
- Regulatory Affairs
- CMC and development teams
- IT and digital transformation teams
- Procurement
- Quality and compliance
Biotechnology companies
Biotech companies increasingly use cloud clinical platforms because they often have smaller internal technology teams and need to scale quickly from Phase I to Phase III.
Their priorities often include:
- Faster study build
- Flexible configuration
- Lower implementation burden
- Patient recruitment
- Data interoperability
- CRO integration
- Global regulatory compliance
CROs
CROs are another major buyer group.
They need platforms that can support multiple sponsors and protocols while maintaining data separation, auditability and standardized workflows.
IQVIA’s 300+ customers and 1,700+ studies illustrate the importance of technology platforms within outsourced clinical development.
Academic medical centers and research sites
Academic institutions have different requirements.
They often prioritize:
- CTMS
- IRB management
- eConsent
- eSource
- Site documentation
- Participant management
- Study finance
- Compliance
This is where platforms such as Advarra, Florence and Castor become particularly important.
What Are Clinical Trial Buyers Looking for in 2026?
The evaluation criteria are changing rapidly.
AI and automation
Sponsors increasingly want AI to reduce manual work in:
- Study build
- Data review
- Query management
- Document classification
- Risk identification
- Site monitoring
- Patient recruitment
- Protocol analysis
Veeva’s Falcon strategy and Medidata’s expansion of AI across clinical workflows illustrate how major vendors are moving from conventional SaaS toward agentic clinical operations.
Interoperability
Clinical trials commonly involve multiple systems.
Buyers increasingly expect platforms to integrate with:
- EHRs
- Laboratory systems
- Imaging platforms
- CTMS
- EDC
- eTMF
- Safety systems
- Wearables
- Connected devices
- CRO systems
This is becoming a major differentiator because fragmented technology creates duplicate data entry and operational burden.
Patient-centric trials
Clinical research is moving toward more flexible participation.
Sponsors increasingly want technology supporting:
- Remote visits
- eConsent
- eCOA
- Wearables
- Connected devices
- Home health
- Telehealth
- Digital biomarkers
This is expanding the addressable market beyond traditional EDC and CTMS.
Real-time data and analytics
Clinical development teams increasingly want continuous visibility into:
- Enrollment
- Site performance
- Protocol deviations
- Data quality
- Patient retention
- Trial milestones
- Safety signals
- Operational risk
The objective is moving from collecting clinical data to generating actionable intelligence during the study.
Competitive Landscape in 2026
The market is not simply a race between the biggest software companies.
There are now several competitive layers.
Enterprise clinical platforms
Medidata, Veeva and Oracle compete for integrated clinical-development environments.
Data and technology ecosystems
IQVIA differentiates through the combination of technology, healthcare data, analytics and CRO capabilities.
Site-centric platforms
Florence and Advarra focus strongly on connecting research sites with sponsors and institutions.
Endpoint specialists
Clario and Signant Health compete in areas such as eCOA, digital endpoints and patient-generated data.
Decentralized trial platforms
Medable and other specialist vendors compete around remote patient participation and hybrid trial execution.
This specialization means the “best” platform depends heavily on the sponsor’s trial design and technology architecture.
The Major Trend: Clinical Trial Platforms Are Becoming AI-Native
The biggest change entering 2026 and 2027 is the transition from software applications to AI-enabled clinical development platforms.
Vendors are increasingly developing AI for:
- Protocol design
- Study configuration
- Patient recruitment
- Site selection
- Data review
- Risk detection
- Document processing
- Trial monitoring
- Patient engagement
- Regulatory workflows
Veeva announced Veeva Falcon, an agentic AI platform designed to support clinical, regulatory and safety workflows, while Medidata is expanding AI across study, patient and data experiences.
This could fundamentally change how clinical operations teams use technology.
Instead of navigating multiple applications manually, teams will increasingly interact with AI agents that execute workflow-specific tasks across connected clinical systems.
What Should Pharma and Biotech Leaders Track?
Companies evaluating clinical trial technology should monitor:
- Platform adoption
- Number of active trials
- Number of patients supported
- Pharma customer penetration
- CRO partnerships
- Site network size
- AI capabilities
- EDC and CTMS integration
- eCOA capabilities
- Decentralized trial capabilities
- EHR interoperability
- Data standards
- Regulatory compliance
- Implementation timelines
- Total cost of ownership
- Global deployment capability
The most important question is no longer simply:
“Which clinical trial software is the biggest?”
It is:
“Which platform can connect the clinical-development ecosystem while reducing operational complexity and improving the quality and speed of evidence generation?”
How Towards Healthcare Research & Consulting Can Help
Towards Healthcare Research & Consulting can help pharmaceutical, biotechnology and healthcare technology companies understand the rapidly changing clinical trial platform landscape.
Our research can track:
- Clinical trial platform market size
- Vendor revenues
- Customer and trial adoption
- EDC and CTMS capabilities
- AI investments
- Platform launches
- Clinical technology partnerships
- M&A activity
- CRO relationships
- Site-network expansion
- Decentralized clinical trial adoption
- Patient engagement technologies
- Competitive positioning
- Buyer requirements
We can also benchmark platforms across enterprise pharma, biotech, CRO, academic and research-site segments.
The strategic opportunity is to understand not only which companies are leading clinical-trial technology in 2026, but also where the next competitive shift is occurring: AI, interoperability, decentralized research, patient-generated data, real-time analytics or end-to-end clinical development platforms.
Connect with us for complete guidance or further enquiry at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium